-
The company completed a $13.4 million B1 round of financing to study in-cell drug use of PARP inhibitors
Time of Update: 2021-02-25
June 20, 2019, Cybrexa Therapeutics, a company focused on research and development of cancer-targeted therapies, announced the completion of a $13.4 million B1 round of financing.
-
Bayer has gained control of the BlueRock stem cell joint venture
Time of Update: 2021-02-25
to differentiate into dopamine-energy neurons, which are gradually destroyed in the disease. It is hoped that introducing these neurons into depleted areas of the brain will lead to increased dopamine release and the restoration of motor function
-
2019 Chinese scientists have published 557 articles in the Cell series
Time of Update: 2021-02-25
, for example, the proportion of papers published in Cell Press's research journals has increased year by year, with the exception of Beijing and Shanghai.
-
JCO: The treatment of rhonamide combined with R-CHOP can prolong the survival of patients with untreated diffuse large B-cell lymphoma
Time of Update: 2021-02-25
For untreated patients with diffuse large B-cell lymphoma (DLBCL) (including COO and ABC-DLBCL subtypes), the Synadamic Unilidoxi monoantigen-cyclophosphamide-dorobi-star-changchun-neo-alkali-pernisson (R-CHOP) program (R2CHOP) can extend its lifetime.
-
Nat Commun: Chromatin accessability of circulating CD8-T cells predicts the response of gastric cancer patients to PD-1 therapy
Time of Update: 2021-02-25
although tumor genomic analysis has identified a small percentage of patients with stomach cancer (GC) who could benefit from anti-PD-1 treatment, not all reactions can be explained by tumor sequencing alone.
-
ASCO GU 2021: The efficacy of the combined treatment of metastatic renal cell carcinoma with Navuliyu monoanti- and Ipi-anti-anti-drugs
Time of Update: 2021-02-25
At present, the combination of Navuliyu monoanti-Ipi monoanti and vascular endodermal growth factor (VEGF) inhibitor immunotherapy is a first-line treatment for metastatic renal cell carcinoma (mRCC).
-
The physical factors affect the development of stem cell collection
Time of Update: 2021-02-25
study further found that internal pressure in mouse embryonic stem cell collection promotes the expression of two genes, Nanog and Oct4, which also have a positive effect on blastocyst development in the supercellular 3D myoglobulin cortical layer.
-
The cell sub-journal reveals how formation cells maintain a steady state of the tymome
Time of Update: 2021-02-25
new study sheds light on the proliferation, migration and cloning of tymular corneal formation cells and reveals their contribution to the maintenance of the tymulate. The eardrum is located at the bottom
-
U.S. researchers are rapidly evolving new molecules in mammalian cells
Time of Update: 2021-02-25
WASHINGTON, July 6 (Xinhua) -- A U.S. research team has developed a fast and precise "targeted evolution" tool that can produce new functional proteins in mammalian cells, which are expected to become drugs for a variety of diseases.
-
Scientists at East China University have discovered a universal protein cell delivery vector
Time of Update: 2021-02-25
protein, red fluorescent protein, yellow fluorescent protein, cytochrome c, lysosin, trypsin, β-semi-lactosinease, saponin, nuclease, keruclein and so on, and can maintain the bioactive activity of these proteins. Cheng Yiyun team
-
U.S. studies have found that cells have some kind of "defect" and live longer
Time of Update: 2021-02-25
defects don't usually mean good things, but a new study in the United States has found that yeast cells live longer if there is some kind of "chromatin structural defect." The findings could help explore similar mechanisms in human cells
-
New technology pulls out 'silent killer' in tumor stem cells
Time of Update: 2021-02-24
Surprisingly, these tumor stem cells are usually in a resting state, with low telomerase activity and the ability to maintain relatively short telomere lengths due to their non-proliferation.
-
Novaral's sickle cell drug gets FDA priority review
Time of Update: 2021-02-24
The regulatory agency accepted the company's Biologics Licensing Application (BLA) for the prevention of vascular ococcytosis (VOCs) in patients with sickle cell disease (SCD) and was awarded a breakthrough treatment designation in December 2018.
-
Ribozymes Targeted Against AML1/MTG8: Evaluation of Ribozyme Efficiency in a Cell-Free System and Transfection with Cationic Liposome
Time of Update: 2021-02-24
Recent studies have revealed that genetic aberrations originated from these chromosomal translocations have a key role in oncogenesis.
-
ASCO GU 2021: What is the effectiveness of immunotherapy in the first line of metastatic renal cell carcinoma?
Time of Update: 2021-02-24
plus ipilimumab combination and the immunotherapy/VEGF inhibitor combination in the IMDC moderate/low-risk population. the combination of severe immuno-related adverse events and improvements in total survival and next treatment time related to nivolumab plus monoantitherapy and immunotherapy/VEGF inhibitors are reasonable first-line strategies
-
The first-line treatment of non-small cell lung cancer by the "Keytruda-Yervoy" therapy in Mesadong failed
Time of Update: 2021-02-24
Mercadon announced on November 9th that it would stop clinical trials codenum KEYNOTE-598, a study on the use of Keytruda in combination with Yervoy® ("K-Y" dual immunotherapy) A first-line treatment for tumor expression PD-L1 (TPS≥50
-
Transforming Lepidopteran Insect Cells for Continuous Recombinant Protein Expression
Time of Update: 2021-02-24
An alternative approach to producing poorly expressed proteins is to transform insect cells with the gene of interest under the control of promoters that are constitutively active in uninfected cells, thereby making cell lines that continuously express recombinant protein.
-
New results in the journal Science: PD-1 Antibody "New Partner" - iNK Cell Therapy
Time of Update: 2021-02-24
the amplification and performance of iNK cells (Source: TranslationAl Medicine) In mouse models of ovarian cancer allogeneic transplantation, iNK cells exhibited strong anti-tumor function, and the tumor burden was significantly and continuously reduced in mice after treatment.
-
iNKT cell therapy "recruiter" - dual-specific antibodies
Time of Update: 2021-02-24
' enthusiasm for cancer treatment by targeting CD1d restrictive iNKT cells. Figure 1 iNKT cell-related therapy | a) uses CD1d-specific exogenetic (Exog) lipid antigens and derivatives to activate iNKT cell response; b) autologic iNKT cell therapy
-
2 "Cells" on the same day: Tumor immunotherapy unlocks new roles Immune system is more resistant to cancer
Time of Update: 2021-02-24
In mice stimulated by β-glucosin, the researchers found that bone marrow hematopoietic stem cells alter gene expression in favor of producing more neutral granulocytes, especially those associated with anti-tumor activity.
